Efficacy of topical dorzolamide 2% in diabetic cystoid macular edema

Efficacy of topical dorzolamide 2% in diabetic cystoid macular edema - Topical dorzolamide 2% in diabetic cystoid macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022608

Enrollment

Registered

2016-06-05

Start date

2014-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diadetic cystoid maculopathy at Mansoura Ophthalmic center -Egypt

Interventions

Details of interventions: Application of dorzolamide 2% eye drop 2% In diabetic cystoid edema Amount, and frequency:3 times /day Duration:for 30 days Follow up for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The diabetic adult patients (type 1 and 2) with cystoids macular edema (CSME) secondary to diabetic retinopathy

Exclusion criteria

Exclusion criteria: Patients had additional ocular diseases (chronic inflammatory, glaucoma, or neoplastic disorders,Patients on other medications may affect the visual acuity and/or retinal function, Advanced diabetic eye disease,Serous retinal detachment,Vitreo-retinal traction syndrome,Mixed maculopathy (macular ischemia by angiography),Prior laser therapy.

Design outcomes

Primary

Measure	Time frame
Eefective in reduction central foveal thickness	—

Secondary

Measure	Time frame
Improvement of BCVA	—

Countries

Africa

Contacts

Public ContactAmani Badwi

Mansoura University-Faculty of Medicine Mansoura Ophthalmic center Ophthalmology department Ophthalmology department

amanibadawi37@yahoo.com0201003818271

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026